Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study
- 1 November 2015
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 170 (5) , 1033-1041.e1
Abstract
No abstract availableKeywords
Funding Information
- Veterans Health Services Research & Development Career Development (CDA09027-1)
- American Heart Association National Scientist Development (09SDG2250647)
- VA Health Services and Development (IIR 09-092)
This publication has 29 references indexed in Scilit:
- Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) studyAmerican Heart Journal, 2013
- Antiarrhythmic Drug Therapy for Atrial FibrillationCirculation, 2012
- Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management)JACC, 2011
- Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillationEP Europace, 2010
- Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide studyEP Europace, 2009
- Survival MethodsCirculation, 2007
- Amiodarone versus Sotalol for Atrial FibrillationNew England Journal of Medicine, 2005
- Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyCirculation, 2004
- Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablationHeart, 2001
- Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillationExpert Opinion on Investigational Drugs, 2000